Food and Drug Administration

Antiviral Drugs Advisory Committee

August 6, 2002

Briefing Information

NDA 21-449 Adefovir dipivoxil, for treatment of chronic hepatitis B (CHB) in adults


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Adefovir Dipivoxil For the Treatment of Chronic Hepatitis B, Gilead Sciences, Inc.  pdf

Replacement page  pdf   htm   doc

Food and Drug Administration Review  doc  htm  pdf

Errata Sheets   pdf   htm   doc